BDX
$224.08
Becton Dickinson
$2.92
1.32%
BDX
Earnings Whisper ®
N/A
4th Quarter September 2020
Consensus:  $2.55
Revenue:  $4.47 Bil
Thursday
Nov 5
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BDX reports earnings?
Beat
Meet
Miss

Where is BDX's stock price going from here?
Up
Flat
Down
Stock chart of BDX
Analysts
Summary of analysts' recommendations for BDX
Score
Grade
Pivots
Resistance
$231.00
$227.79
$225.93

$222.72

Support
$220.86
$217.65
$215.79
Tweet
Growth
Description
Becton, Dickinson & Company is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues.
Peers
StrykerBoston ScientificBaxter InternationalAbbottWatersCardiovascular SystemsIntegra LifeSciences HoldingsTeleflex3MHill-Rom Holdings